Eliquis Market Size to Hit USD 31.74 Billion by 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Eliquis Market

5.1. COVID-19 Landscape: Eliquis Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Eliquis Market, By Indication / Application

8.1. Eliquis Market Revenue and Volume Forecast, by Indication / Application

8.1.1. Non-valvular Atrial Fibrillation (NVAF) – stroke/systemic embolism prevention

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Deep Vein Thrombosis (DVT) treatment/prevention

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Pulmonary Embolism (PE) treatment/prevention

8.1.3.1. Market Revenue and Volume Forecast

8.1.4. Post-operative VTE prophylaxis (e.g., hip/knee replacement)

8.1.4.1. Market Revenue and Volume Forecast

Chapter 9. Global Eliquis Market, By Strength / Dosage

9.1. Eliquis Market Revenue and Volume Forecast, by Strength / Dosage

9.1.1. 5 mg tablets

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. 2.5 mg tablets

9.1.2.1. Market Revenue and Volume Forecast

Chapter 10. Global Eliquis Market, By Distribution Channel

10.1. Eliquis Market Revenue and Volume Forecast, by Distribution Channel

10.1.1. Hospital Pharmacies

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Retail Pharmacies

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Online Pharmacies

10.1.3.1. Market Revenue and Volume Forecast

10.1.4. Mail-Order Pharmacies

10.1.4.1. Market Revenue and Volume Forecast

Chapter 11. Global Eliquis Market, By Payer / Pricing Model

11.1. Eliquis Market Revenue and Volume Forecast, by Payer / Pricing Model

11.1.1. Insured/reimbursed (commercial/Medicare)

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Direct-to-consumer (cash/discount programs)

11.1.2.1. Market Revenue and Volume Forecast

Chapter 12. Global Eliquis Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Volume Forecast, by Indication / Application

12.1.2. Market Revenue and Volume Forecast, by Strength / Dosage

12.1.3. Market Revenue and Volume Forecast, by Distribution Channel

12.1.4. Market Revenue and Volume Forecast, by Payer / Pricing Model

12.1.5. U.S.

12.1.5.1. Market Revenue and Volume Forecast, by Indication / Application

12.1.5.2. Market Revenue and Volume Forecast, by Strength / Dosage

12.1.5.3. Market Revenue and Volume Forecast, by Distribution Channel

12.1.5.4. Market Revenue and Volume Forecast, by Payer / Pricing Model

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Volume Forecast, by Indication / Application

12.1.6.2. Market Revenue and Volume Forecast, by Strength / Dosage

12.1.6.3. Market Revenue and Volume Forecast, by Distribution Channel

12.1.6.4. Market Revenue and Volume Forecast, by Payer / Pricing Model

12.2. Europe

12.2.1. Market Revenue and Volume Forecast, by Indication / Application

12.2.2. Market Revenue and Volume Forecast, by Strength / Dosage

12.2.3. Market Revenue and Volume Forecast, by Distribution Channel

12.2.4. Market Revenue and Volume Forecast, by Payer / Pricing Model

12.2.5. UK

12.2.5.1. Market Revenue and Volume Forecast, by Indication / Application

12.2.5.2. Market Revenue and Volume Forecast, by Strength / Dosage

12.2.5.3. Market Revenue and Volume Forecast, by Distribution Channel

12.2.5.4. Market Revenue and Volume Forecast, by Payer / Pricing Model

12.2.6. Germany

12.2.6.1. Market Revenue and Volume Forecast, by Indication / Application

12.2.6.2. Market Revenue and Volume Forecast, by Strength / Dosage

12.2.6.3. Market Revenue and Volume Forecast, by Distribution Channel

12.2.6.4. Market Revenue and Volume Forecast, by Payer / Pricing Model

12.2.7. France

12.2.7.1. Market Revenue and Volume Forecast, by Indication / Application

12.2.7.2. Market Revenue and Volume Forecast, by Strength / Dosage

12.2.7.3. Market Revenue and Volume Forecast, by Distribution Channel

12.2.7.4. Market Revenue and Volume Forecast, by Payer / Pricing Model

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Volume Forecast, by Indication / Application

12.2.8.2. Market Revenue and Volume Forecast, by Strength / Dosage

12.2.8.3. Market Revenue and Volume Forecast, by Distribution Channel

12.2.8.4. Market Revenue and Volume Forecast, by Payer / Pricing Model

12.3. APAC

12.3.1. Market Revenue and Volume Forecast, by Indication / Application

12.3.2. Market Revenue and Volume Forecast, by Strength / Dosage

12.3.3. Market Revenue and Volume Forecast, by Distribution Channel

12.3.4. Market Revenue and Volume Forecast, by Payer / Pricing Model

12.3.5. India

12.3.5.1. Market Revenue and Volume Forecast, by Indication / Application

12.3.5.2. Market Revenue and Volume Forecast, by Strength / Dosage

12.3.5.3. Market Revenue and Volume Forecast, by Distribution Channel

12.3.5.4. Market Revenue and Volume Forecast, by Payer / Pricing Model

12.3.6. China

12.3.6.1. Market Revenue and Volume Forecast, by Indication / Application

12.3.6.2. Market Revenue and Volume Forecast, by Strength / Dosage

12.3.6.3. Market Revenue and Volume Forecast, by Distribution Channel

12.3.6.4. Market Revenue and Volume Forecast, by Payer / Pricing Model

12.3.7. Japan

12.3.7.1. Market Revenue and Volume Forecast, by Indication / Application

12.3.7.2. Market Revenue and Volume Forecast, by Strength / Dosage

12.3.7.3. Market Revenue and Volume Forecast, by Distribution Channel

12.3.7.4. Market Revenue and Volume Forecast, by Payer / Pricing Model

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Volume Forecast, by Indication / Application

12.3.8.2. Market Revenue and Volume Forecast, by Strength / Dosage

12.3.8.3. Market Revenue and Volume Forecast, by Distribution Channel

12.3.8.4. Market Revenue and Volume Forecast, by Payer / Pricing Model

12.4. MEA

12.4.1. Market Revenue and Volume Forecast, by Indication / Application

12.4.2. Market Revenue and Volume Forecast, by Strength / Dosage

12.4.3. Market Revenue and Volume Forecast, by Distribution Channel

12.4.4. Market Revenue and Volume Forecast, by Payer / Pricing Model

12.4.5. GCC

12.4.5.1. Market Revenue and Volume Forecast, by Indication / Application

12.4.5.2. Market Revenue and Volume Forecast, by Strength / Dosage

12.4.5.3. Market Revenue and Volume Forecast, by Distribution Channel

12.4.5.4. Market Revenue and Volume Forecast, by Payer / Pricing Model

12.4.6. North Africa

12.4.6.1. Market Revenue and Volume Forecast, by Indication / Application

12.4.6.2. Market Revenue and Volume Forecast, by Strength / Dosage

12.4.6.3. Market Revenue and Volume Forecast, by Distribution Channel

12.4.6.4. Market Revenue and Volume Forecast, by Payer / Pricing Model

12.4.7. South Africa

12.4.7.1. Market Revenue and Volume Forecast, by Indication / Application

12.4.7.2. Market Revenue and Volume Forecast, by Strength / Dosage

12.4.7.3. Market Revenue and Volume Forecast, by Distribution Channel

12.4.7.4. Market Revenue and Volume Forecast, by Payer / Pricing Model

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Volume Forecast, by Indication / Application

12.4.8.2. Market Revenue and Volume Forecast, by Strength / Dosage

12.4.8.3. Market Revenue and Volume Forecast, by Distribution Channel

12.4.8.4. Market Revenue and Volume Forecast, by Payer / Pricing Model

12.5. Latin America

12.5.1. Market Revenue and Volume Forecast, by Indication / Application

12.5.2. Market Revenue and Volume Forecast, by Strength / Dosage

12.5.3. Market Revenue and Volume Forecast, by Distribution Channel

12.5.4. Market Revenue and Volume Forecast, by Payer / Pricing Model

12.5.5. Brazil

12.5.5.1. Market Revenue and Volume Forecast, by Indication / Application

12.5.5.2. Market Revenue and Volume Forecast, by Strength / Dosage

12.5.5.3. Market Revenue and Volume Forecast, by Distribution Channel

12.5.5.4. Market Revenue and Volume Forecast, by Payer / Pricing Model

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Volume Forecast, by Indication / Application

12.5.6.2. Market Revenue and Volume Forecast, by Strength / Dosage

12.5.6.3. Market Revenue and Volume Forecast, by Distribution Channel

12.5.6.4. Market Revenue and Volume Forecast, by Payer / Pricing Model

Chapter 13. Company Profiles

13.1. Bristol-Myers Squibb

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Pfizer

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Sanofi

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Johnson & Johnson (Janssen—Pradaxa competitor)

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Hikma Pharmaceuticals

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Lupin

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Aspen Pharmacare

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Apotex

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Generic manufacturers (collective)

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Novartis (Sandoz)

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The eliquis market size is expected to increase from USD 20.15 billion in 2024 to USD 31.74 billion by 2034.

The eliquis market is expected to grow at a compound annual growth rate (CAGR) of around 4.65% from 2025 to 2034.

The major players in the eliquis market include Bristol-Myers Squibb, Pfizer, Bayer, Teva Pharmaceutical, Mylan, Dr. Reddy’s Laboratories, Cipla, Sun Pharmaceutical Industries, Sanofi, Novartis (Sandoz), Johnson & Johnson, Boehringer Ingelheim, AstraZeneca, GSK, Merck & Co., Hikma Pharmaceuticals, Lupin, Aspen Pharmacare, Apotex, and Generic manufacturers (collective).

The driving factors of the eliquis market are the increasing incidences of fatal illnesses like CVDs, cancer, which can be treated effectively by the Eliquis molecule, which is supported by regulatory bodies as well.

North America region will lead the global eliquis market during the forecast period 2025 to 2034.